Xenetic Biosciences Signs a Research Agreement with the University of Virginia to Advance DNase-Based Oncology Platform
Shots:
- Xenetic Biosciences and the University of Virginia have signed a research funding agreement and a material transfer agreement for the development of its systemic DNase program
- As per the agreement, Xenetic has the option to acquire an exclusive license for new intellectual property from the DNase research program along with advancing existing intellectual property. It is progressing toward its FIH study to assess DNase combined with immune checkpoint inhibitors or CT
- Xenetic's DNase-oncology platform targets neutrophil extracellular traps (NETs), released by activated neutrophils in response to microbial or pro-inflammatory challenges
Ref: Xenetic Biosciences | Image: Xenetic Biosciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
